Precision Care Technologies, a Boomerang Ventures portfolio company pioneering Quantifiable Soft Tissue Manipulation (QSTM) technology, today announced the appointment of Jennifer Holmes as Chief Executive Officer. Holmes brings three decades of executive leadership in the medical device and MedTech sectors, with a proven track record of driving commercialization, operational development, and strategic market expansion.
“Jennifer’s expertise in leading go-to-market strategies and scaling MedTech companies makes her an ideal fit for Precision Care Technologies,” said Eric Beier, MD, Partner and Chief Medical Officer, Boomerang Ventures. “Her leadership will be instrumental in advancing musculoskeletal soft tissue therapy with QSTM technology and empowering clinicians with analytics-powered solutions.”
Holmes joins Precision Care Technologies with extensive experience in disruptive healthcare technology companies, most recently serving as CEO of Rehab Boost, Inc., where she successfully guided the company through a merger and acquisition. She has held leadership positions at major healthcare and MedTech firms, including Boston Scientific, Guidant Corporation (Abbott), Spectranetics (Philips), MedAssets (Vizient), and Central Logic (ABOUT Healthcare). Her expertise spans enterprise sales, revenue growth, strategic planning, and executing high-impact commercial operating plans.
“I’m excited to join Precision Care Technologies at such a pivotal early stage,” said Holmes. “With the increasing demand for objective, measurable solutions in musculoskeletal therapy, QSTM technology has the potential to transform patient outcomes and establish new standards of care. I’m ready to work with the team to bring this innovation to the forefront of clinical practice.”
Precision Care Technologies’ QSTM technology targets redefining manual therapy by providing clinicians with real-time, measurable metrics-including force, angle, cadence, and area-ensuring precision and consistency in patient treatment. By turning subjective techniques into objective data, QSTM empowers physical therapists, chiropractors, and rehabilitation specialists to enhance care quality and optimize recovery outcomes.
Musculoskeletal injuries represent a significant burden on the healthcare system, with an estimated 63 million work, sport, and other injuries occurring annually in the U.S., resulting in $1.28 trillion in costs. These injuries are predominantly treated by physical therapists, chiropractors, athletic trainers, and other rehabilitation specialists, according to research. Additionally, millions of physical therapy visits occur each year, with 70-80% involving soft tissue manual therapy. Despite its widespread use, manual therapy remains largely subjective, with limited tools available to measure treatment history, process, and outcomes. QSTM technology addresses this gap by providing clinicians with precise, quantifiable data, ensuring consistent, objective, and effective patient care.
The idea for QSTM originated from Terry Loghmani, PT, Ph.D., Associate Professor in the Department of Physical Therapy at Indiana University’s School of Health and Human Sciences. Dr. Loghmani, an expert in orthopedic manual therapy and Instrument-Assisted Soft Tissue Mobilization (IASTM), recognized the need for a tool that could provide real-time, measurable therapy metrics. She co-founded Health Smart Technologies with Sohel Anwar, PE, Ph.D., and Stanley Chien, ECE, Ph.D., of Purdue School of Engineering and Technology at IUPUI. In August 2023, Boomerang Ventures acquired Health Smart Technologies, rebranding the business as Precision Care Technologies (formerly BVS Muscle) as a new portfolio company. With this acquisition, Precision Care Technologies now exclusively licenses the QSTM device system developed at IU, marking a significant advancement in musculoskeletal soft tissue therapy.
“With Jennifer at the helm, we are confident in Precision Care Technologies’ ability to scale operations, expand market adoption, and further the mission of revolutionizing soft tissue therapy,” added Beier. “Her leadership will be key in accelerating a shared vision for a future where every patient receives exceptional, data-driven care.”
Source: Business Insider, March 4, 2025
